Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Leqembi, a new biotech drug, has been approved in the UK, but reimbursement may not follow due to concerns about the cost to the NHS. The FDA defended its med device chief's tenure after ethics concerns were raised. Employers are expecting higher health costs next year, driven by rising pharmacy spending on drugs like GLP-1 for obesity. BridgeBio has sent rare disease drugs to a new company called GondolaBio, backed by investors including Viking Global Investors and Sequoia Capital. Versant has launched a new startup called Borealis Biosciences with funding from Novartis.New Jersey has announced plans to erase $100 million in medical debt for nearly 50,000 residents, following similar initiatives by other states and federal regulators. Molina Healthcare has extended CEO Joe Zubretsky's contract through 2027, along with a stock grant potentially worth $51 million. Additionally, CMS has received 12,000 complaints of noncompliance with the No Surprises Act, resulting in $1.7 million in restitution.Novartis and Versant have launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases, following the success of Chinook Therapeutics. Meanwhile, Wuxi Biologics reported a 24% drop in net profit in the first half of 2024 despite signing a record number of new projects. In other news, Biogen and Eisai's Alzheimer's drug Leqvembi has been approved in the UK but deemed too expensive by NICE, while Biomarin has brought on Roche and Amgen alums in an executive restructuring.The text discusses the potential impact of the Democrats' proposed changes to Medicare drug price negotiations on the pharmaceutical industry's research and development (R&D) efforts. Kamala Harris is expected to address these issues during the Democratic National Convention, with the party aiming to lower drug prices by increasing the number of drugs subject to negotiations.TE Connectivity offers sensor solutions for minimally invasive devices, providing precision and safety for procedures such as cardiac mapping and ablation. Their sensor technology can enhance efficacy in heart arrhythmia treatments. The comprehensive sensor solutions guide provides detailed applications, key features, and benefits of their sensors.The text discusses the importance of collecting and using social determinants of health (SDOH) data in health economics and outcomes research (HEOR). It highlights the challenges of collecting SDOH data and provides insights on how to effectively use the data while ensuring privacy and security. The text emphasizes the significance of diverse and inclusive research practices, evaluating data validity and sourcing, and effectively utilizing SDOH data to gain more accurate insights in HEOR.